CNBC's full interview with Biogen CEO on new Alzheimer's drug

Biogen's Alzheimer's drug Aducanumab has won FDA approval. CEO Michel Vounatsos joins CNBC's Meg Tirrell on 'Power Lunch' to discuss the approval, how the drug works and how it could change the diagnosis for Alzheimer's disease.